Faron Pharmaceuticals (LSE:FARN) has issued its Annual Report for 2025, providing shareholders with detailed updates on the company’s financial results, governance framework and progress across its clinical development programmes. The report includes the Board of Directors’ report, audited financial statements and the remuneration report.
The document also outlines developments related to Faron’s lead immunotherapy candidate, bexmarilimab, including progress in the ongoing Phase I/II BEXMAB clinical study targeting aggressive blood cancers. The annual report is available in both English and Finnish on the company’s website, offering investors broader access to information on the company’s strategy and research progress.
Publishing the full report in two languages reflects Faron’s commitment to transparency and regulatory compliance across its dual listings on the AIM market in London and Nasdaq First North. The disclosures provide stakeholders with greater visibility into the company’s operations as it continues to advance its oncology pipeline.
Faron hopes the detailed reporting will help maintain engagement with existing shareholders while also supporting interest from potential investors as it works to strengthen its position within the competitive field of cancer immunotherapy development.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd, headquartered in Turku, Finland, is a clinical-stage biopharmaceutical company developing new immunotherapies designed to activate the body’s immune system against cancer. Its lead programme, bexmarilimab, is being tested in several clinical studies for hematological cancers such as acute myeloid leukemia and myelodysplastic syndrome, as well as in solid tumors, often alongside established treatment regimens.
Leave a Reply